SkatoleAndrostenes: Unsaturated derivatives of the steroid androstane containing at least one double bond at any site in any of the rings.Meat: The edible portions of any animal used for food including domestic mammals (the major ones being cattle, swine, and sheep) along with poultry, fish, shellfish, and game.Swine: Any of various animals that constitute the family Suidae and comprise stout-bodied, short-legged omnivorous mammals with thick skin, usually covered with coarse bristles, a rather long mobile snout, and small tail. Included are the genera Babyrousa, Phacochoerus (wart hogs), and Sus, the latter containing the domestic pig (see SUS SCROFA).Odors: The volatile portions of substances perceptible by the sense of smell. (Grant & Hackh's Chemical Dictionary, 5th ed)Orchiectomy: The surgical removal of one or both testicles.Testosterone: A potent androgenic steroid and major product secreted by the LEYDIG CELLS of the TESTIS. Its production is stimulated by LUTEINIZING HORMONE from the PITUITARY GLAND. In turn, testosterone exerts feedback control of the pituitary LH and FSH secretion. Depending on the tissues, testosterone can be further converted to DIHYDROTESTOSTERONE or ESTRADIOL.Smell: The ability to detect scents or odors, such as the function of OLFACTORY RECEPTOR NEURONS.Castration: Surgical removal or artificial destruction of gonads.ChicagoDehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.Adrenal Cortex: The outer layer of the adrenal gland. It is derived from MESODERM and comprised of three zones (outer ZONA GLOMERULOSA, middle ZONA FASCICULATA, and inner ZONA RETICULARIS) with each producing various steroids preferentially, such as ALDOSTERONE; HYDROCORTISONE; DEHYDROEPIANDROSTERONE; and ANDROSTENEDIONE. Adrenal cortex function is regulated by pituitary ADRENOCORTICOTROPIN.Androgens: Compounds that interact with ANDROGEN RECEPTORS in target tissues to bring about the effects similar to those of TESTOSTERONE. Depending on the target tissues, androgenic effects can be on SEX DIFFERENTIATION; male reproductive organs, SPERMATOGENESIS; secondary male SEX CHARACTERISTICS; LIBIDO; development of muscle mass, strength, and power.Contrast Media: Substances used to allow enhanced visualization of tissues.Androstenedione: A delta-4 C19 steroid that is produced not only in the TESTIS, but also in the OVARY and the ADRENAL CORTEX. Depending on the tissue type, androstenedione can serve as a precursor to TESTOSTERONE as well as ESTRONE and ESTRADIOL.Adrenal Glands: A pair of glands located at the cranial pole of each of the two KIDNEYS. Each adrenal gland is composed of two distinct endocrine tissues with separate embryonic origins, the ADRENAL CORTEX producing STEROIDS and the ADRENAL MEDULLA producing NEUROTRANSMITTERS.Receptors, Androgen: Proteins, generally found in the CYTOPLASM, that specifically bind ANDROGENS and mediate their cellular actions. The complex of the androgen and receptor migrates to the CELL NUCLEUS where it induces transcription of specific segments of DNA.Steroids: A group of polycyclic compounds closely related biochemically to TERPENES. They include cholesterol, numerous hormones, precursors of certain vitamins, bile acids, alcohols (STEROLS), and certain natural drugs and poisons. Steroids have a common nucleus, a fused, reduced 17-carbon atom ring system, cyclopentanoperhydrophenanthrene. Most steroids also have two methyl groups and an aliphatic side-chain attached to the nucleus. (From Hawley's Condensed Chemical Dictionary, 11th ed)PolysaccharidesAdrenal Cortex Neoplasms: Tumors or cancers of the ADRENAL CORTEX.EstersHeparitin Sulfate: A heteropolysaccharide that is similar in structure to HEPARIN. It accumulates in individuals with MUCOPOLYSACCHARIDOSIS.Sulfates: Inorganic salts of sulfuric acid.Sulfuric Acids: Inorganic and organic derivatives of sulfuric acid (H2SO4). The salts and esters of sulfuric acid are known as SULFATES and SULFURIC ACID ESTERS respectively.SulfatasesSulfuric Acid Esters: Organic esters of sulfuric acid.Arylsulfatases: Enzymes that catalyze the hydrolysis of a phenol sulfate to yield a phenol and sulfate. Arylsulfatase A, B, and C have been separated. A deficiency of arylsulfatases is one of the causes of metachromatic leukodystrophy (LEUKODYSTROPHY, METACHROMATIC). EC 3.1.6.1.Dermatan Sulfate: A naturally occurring glycosaminoglycan found mostly in the skin and in connective tissue. It differs from CHONDROITIN SULFATE A (see CHONDROITIN SULFATES) by containing IDURONIC ACID in place of glucuronic acid, its epimer, at carbon atom 5. (from Merck, 12th ed)Heparan Sulfate Proteoglycans: Ubiquitous macromolecules associated with the cell surface and extracellular matrix of a wide range of cells of vertebrate and invertebrate tissues. They are essential cofactors in cell-matrix adhesion processes, in cell-cell recognition systems, and in receptor-growth factor interactions. (From Cancer Metastasis Rev 1996; 15(2): 177-86; Hepatology 1996; 24(3): 524-32)Keratan Sulfate: A sulfated mucopolysaccharide initially isolated from bovine cornea. At least two types are known. Type I, found mostly in the cornea, contains D-galactose and D-glucosamine-6-O-sulfate as the repeating unit; type II, found in skeletal tissues, contains D-galactose and D-galactosamine-6-O-sulfate as the repeating unit.Nuclear Receptor Subfamily 1, Group F, Member 3: An orphan nuclear receptor found in the THYMUS where it plays a role in regulating the development and maturation of thymocytes. An isoform of this protein, referred to as RORgammaT, is produced by an alternatively transcribed mRNA.Nuclear Receptor Subfamily 1, Group F, Member 1: A DNA-binding orphan nuclear receptor that positively regulates expression of ARNTL TRANSCRIPTION FACTORS and is a regulatory component of the circadian clock system. The protein also has a role in neuron cell survival and differentiation in that loss of function mutations of its gene result in the mouse phenotype referred to as the STAGGERER MOUSE.Nuclear Receptor Subfamily 1, Group F, Member 2: An orphan nuclear receptor that is expressed at high levels in neuronal tissues, the RETINA; EPIDIDYMIS; and VAS DEFERENS. The receptor is believed to play a role in regulating a variety of functions including the processing of sensory information, the differentiation of PHOTORECEPTOR CELLS and the CIRCADIAN RHYTHM.Gene Expression Profiling: The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell.Receptor Tyrosine Kinase-like Orphan Receptors: A family of cell surface receptors that were originally identified by their structural homology to neurotropic TYROSINE KINASES and referred to as orphan receptors because the associated ligand and signaling pathways were unknown. Evidence for the functionality of these proteins has been established by experiments showing that disruption of the orphan receptor genes results in developmental defects.Gene Regulatory Networks: Interacting DNA-encoded regulatory subsystems in the GENOME that coordinate input from activator and repressor TRANSCRIPTION FACTORS during development, cell differentiation, or in response to environmental cues. The networks function to ultimately specify expression of particular sets of GENES for specific conditions, times, or locations.Receptors, Thyroid Hormone: Specific high affinity binding proteins for THYROID HORMONES in target cells. They are usually found in the nucleus and regulate DNA transcription. These receptors are activated by hormones that leads to transcription, cell differentiation, and growth suppression. Thyroid hormone receptors are encoded by two genes (GENES, ERBA): erbA-alpha and erbA-beta for alpha and beta thyroid hormone receptors, respectively.Receptors, Retinoic Acid: Proteins in the nucleus or cytoplasm that specifically bind RETINOIC ACID or RETINOL and trigger changes in the behavior of cells. Retinoic acid receptors, like steroid receptors, are ligand-activated transcription regulators. Several types have been recognized.Receptors, Cytoplasmic and Nuclear: Intracellular receptors that can be found in the cytoplasm or in the nucleus. They bind to extracellular signaling molecules that migrate through or are transported across the CELL MEMBRANE. Many members of this class of receptors occur in the cytoplasm and are transported to the CELL NUCLEUS upon ligand-binding where they signal via DNA-binding and transcription regulation. Also included in this category are receptors found on INTRACELLULAR MEMBRANES that act via mechanisms similar to CELL SURFACE RECEPTORS.Transcription Factors: Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process.

Identification of 17-methyl-18-norandrosta-5,13(17-dien-3beta-ol, the C19 fragment formed by adrenal side chain cleavage of a 20-aryl analog of (20S)-20-hydroxycholesterol. (1/115)

Incubation of (20R)-20-phenyl-5-pregnene-3beta,20-diol, an aromatic analog of (23S)-20-hydroxycholesterol, with an adrenal mitochondrial preparation leads to the formation of four compounds: pregnenolone, phenol, a C8 ketone, acetophenone, and a nonpolar C19 compound. This latter compound has now been identified by reverse isotope dilution analysis and by gas chromatography/mass spectrometry as 17-methyl-18-norandrosta-5,13(17)-dien-3beta-ol. From these results it is evident that enzymatic fission of the C-17,20 bond of this synthetic derivative occurs. On the other hand, when (20S)-20-hydroxy[21-14C]cholesterol was used as substrate, the analogous cleavage did not take place. Thus, substitution of an aromatic group on C-20 facilitates side chain cleavage between that carbon atom and the nucleus whereas neither of the naturally occuring precursors, cholesterol or its 20-hydroxylated counterpart, are metabolized to a C8 fragment.  (+info)

Characterization of ovarian carbonyl reductase gene expression during ovulation in the gonadotropin-primed immature Rat. (2/115)

In this differential-display polymerase chain reaction-based study, four different primer sets generated cDNA fragments of ovarian carbonyl reductase genes that were uniquely expressed during the ovulatory process in eCG-primed immature rats. The temporal pattern of expression of this aldo-keto reductase gene was delineated by extracting ovarian RNA at 0, 2, 4, 8, 12, and 24 h after induction of ovulation via injection of the primed animals with hCG. The results showed that at least four homologous forms of this gene were transcribed during ovulation. Northern blot analyses indicated a 14-fold increase in ovarian mRNA for carbonyl reductase, with expression reaching a peak at 8 h after hCG treatment and then declining to negligible levels during the next 16 h. In situ hybridization revealed that most of the transcription was in the thecal connective tissue of the ovary and was absent from the granulosa layer of ovarian follicles. Treatment of the animals with ovulation-blocking doses of epostane (an inhibitor of progesterone synthesis) or indomethacin (an inhibitor of prostanoid synthesis) did not reduce the expression of ovarian carbonyl reductase. Nevertheless, the temporal pattern of expression of carbonyl reductase after the induction of ovulation suggests that this enzyme activity is at least indirectly associated with the ovulatory process.  (+info)

Involvement of progesterone in gonadotrophin-induced pituitary adenylate cyclase-activating polypeptide gene expression in pre-ovulatory follicles of rat ovary. (3/115)

The present study was designed to determine whether progesterone might have a role in gonadotrophin-induced pituitary adenylate cyclase-activating polypeptide (Pacap) gene expression in rat ovary. Northern blot analysis revealed that treatment of pregnant mare's serum gonadotrophin (PMSG)-primed immature rats with the progestin antagonist RU486 or an inhibitor of 3beta-hydroxysteroid dehydrogenase epostane, 1 h before HCG, resulted in a dose-dependent inhibition of the HCG-induced Pacap gene expression. In-situ hybridization demonstrated that the number of pre-ovulatory follicles expressing Pacap mRNA in their granulosa cells was greatly reduced in ovaries treated with RU486. Moreover, the suppressive effect of RU486 or epostane on the LH-induced Pacap gene expression in cultured pre-ovulatory follicles was reversed by co-treatment with the synthetic progestin R5020. We further cloned the 5'-flanking region of the rat Pacap gene and identified the presence of a consensus progesterone receptor element. When luciferase fusion genes containing Pacap gene promoter were transiently transfected into granulosa cells of pre-ovulatory follicles, luciferase activity was markedly stimulated by LH. Treatment with RU486 or epostane resulted in partial suppression of LH-stimulated PACAP promoter activity. Taken together, these results indicate that progesterone, acting through progesterone receptors, plays a role in gonadotrophin induction of Pacap gene expression in granulosa cells of pre-ovulatory follicles, and thereby may be involved in the process of ovulation.  (+info)

Ovarian expression of a disintegrin and metalloproteinase with thrombospondin motifs during ovulation in the gonadotropin-primed immature rat. (4/115)

Mammalian ovulation is a dynamic process that requires degradation of the collagenous connective tissue in the thecal layers of a mature follicle. In this reverse transcription-polymerase chain reaction differential display study, gonadotropin-primed immature rats were used to detect ovarian expression of a relatively new type of disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS-1) that is known to cleave extracellular matrix in acutely inflamed tissues. Immature Wistar rats were primed with 10 IU eCG s. c., and the temporal pattern of expression of the ADAMTS-1 gene was delineated by extracting ovarian RNA at 0, 2, 4, 8, 12, and 24 h after induction of ovulation by injecting the primed animals with 10 IU hCG s.c. The differential display data, Northern analyses, and in situ hybridization micrographs all showed significant up-regulation of ADAMTS-1 gene expression by 8 h after hCG administration. The in situ data indicated that the ADAMTS-1 mRNA was in the granulosa layer of mature follicles. Expression reached a peak at 12 h and remained elevated at 24 h after hCG. ADAMTS-1 gene expression was impaired by the antiprogesterone agent epostane, but this inhibition could be overcome by exogenous progesterone. ADAMTS-1 expression was not affected when ovulation was blocked by treatment of the animals with the anti-eicosanoid agent indomethacin. In conclusion, the temporal pattern of expression of this gene, and its apparent regulation by progesterone, suggests that ADAMTS-1 has a significant role in the inflammatory events of the ovulatory process.  (+info)

Positive relationship between menstrual synchrony and ability to smell 5alpha-androst-16-en-3alpha-ol. (5/115)

To explore the possibility that compounds which were identified as pheromones in experimental animals mediate human menstrual synchrony, we examined the relationship between menstrual synchrony and the ability to smell putative pheromones, 5alpha-androst-16-en-3alpha-ol (3alpha-androstenol) and 5alpha-androst-16-en-3-one (5alpha-androstenone). When we examined menstrual synchrony among 64 women living together in a college dormitory, we found that 24 (38%) of them became synchronized with room-mates in 3 months. Afterwards, dilution series of 3alpha-androstenol and 5alpha-androstenone and the control odorant (pyridine) were presented to the 64 women and sensitivity to the odors was compared between synchronized and non-synchronized women. No difference was found between the two groups of women in the detection threshold for pyridine, indicating that general olfactory ability did not differ between them. The detection threshold for 3alpha-androstenol of synchronized women was significantly lower than that of non-synchronized women, but no difference in the threshold for 5alpha-androstenone was found between synchronized and non-synchronized women. These results indicate that the women who showed menstrual synchrony had a higher sensitivity to 3alpha-androstenol but not necessarily to 5alpha-androstenone.  (+info)

Effects of 5alpha-androst-16-en-3alpha-ol on the pulsatile secretion of luteinizing hormone in human females. (6/115)

We examined the effects of 5alpha-androst-16-en-3alpha-ol (3alpha-androstenol) on pulsatile luteinizing hormone (LH) secretion in human females. The frequency of the LH pulse in the follicular phase was decreased by exposing the women to 3alpha-androstenol.  (+info)

Humoral pathway for local transfer of the priming pheromone androstenol from the nasal cavity to the brain and hypophysis in anaesthetized gilts. (7/115)

It is generally accepted that pheromones act by stimulating of the dendritic receptors of the olfactory neurones massed in the olfactory epithelium. This study was designed to ascertain whether it is possible for the boar pheromone androstenol (5alpha-androst-16-en-3-ol) to be transported from the nasal cavity of anaesthetized gilts to the brain and hypophysis via local transfer from the blood in the perihypophyseal vascular complex. The experiment was performed on days 18-21 of the porcine oestrous cycle (crossbred gilts, n = 6). Tritiated androstenol (3H-A; total amount 10(8) d.p.m. (758 ng)) was applied for 1 min onto the respiratory part of the nasal mucosa, 4-6 cm from the opening of the nares. Arterial blood samples from the aorta and from the carotid rete were collected every 2 min during the 60 min period following administration of the steroid. Total radioactive venous effluent from the head was removed and an adequate volume of homologous blood was transfused into the heart through the carotid external vein. At the end of the experiment gilts were killed and tissue samples of the hypophysis and some brain structures were collected to measure radioactivity. In addition, corresponding control tissues were collected from three untreated gilts and from three heads of gilts 60 min after 3H-A was applied post mortem into the nasal cavity. The concentration of 3H-A was significantly higher (P < 0.0001) in the arterial blood of the carotid rete than that of aorta. The mean rate of 3H-A counter current transfer from venous to arterial blood in the perihypophyseal vascular complex, expressed as the ratio of the 3H-A concentration in arterial blood of the carotid rete to the 3H-A concentration in blood sampled simultaneously from the aorta, was 1.96 +/- 0.1. The concentration of 3H-A in plasma from the venous effluent from the head ranged from 1.3 to 1.8 pg x ml(-1). During the 60 min period of the experiment, 0.68% of the total applied dose of 3H-A was resorbed from the nasal cavity into the venous blood. Moreover, we found that 3H-A was present in the olfactory bulb (P <0.01), amygdala, septum, hypothalamus, adenohypophysis, neurohypophysis (P > 0.05) and perihypophyseal vascular complex (P < 0.01). These results demonstrate that, in anaesthetized gilts, the boar pheromone androstenol may be resorbed from the nasal mucosa, transferred in the perihypophyseal vascular complex into arterial blood supplying the brain and hypophysis, and then arrested in the hypophysis and certain brain structures. We suggest that in addition to the standard neural pathway for signalling pheromones, another pathway exists whereby androstenol, as a priming pheromone, may be resorbed from the nasal cavity into the bloodstream and then pass locally from the perihypophyseal vascular complex into the arterial blood supplying the brain and hypophysis, thus avoiding the first passage metabolism in the liver.  (+info)

Demonstration of 2-unsaturated C19-steroids in the urine of female Asian elephants, Elephas maximus, and their dependence on ovarian activity. (8/115)

Air-borne volatile substances have been demonstrated to signal oestrus, induce ovulation and synchronize ovarian activity in different mammals. An oestrous-related pheromone of the female Asian elephant (Elephas maximus) is known to induce behavioural responses in elephant bulls. Additional data revealed that timing of oestrus in females with close social relationships tends to be synchronized. Therefore, urine from female Asian elephants might be expected to contain luteal phase-dependent volatile substances, which may function as additional chemical signals in this species. The aim of the present study was to identify such compounds and to investigate their pattern of excretion throughout the ovarian cycle. Urine samples were collected three times a week during the follicular phase and one to three times a week during the luteal phase from five adult female Asian elephants from a total of 13 non-conception cycles and one conception cycle, including the first 72 weeks of pregnancy. A simple headspace solid-phase microextraction method has been developed for quantification of urinary volatile substances and analysis was performed by gas chromatography. The comparison of urine collected during the follicular and the luteal phase indicated the presence of two luteal phase-dependent substances. Mass spectrometry was used to identify one substance as 5alpha-androst-2-en-17-one and a second substance as the corresponding alcoholic compound 5alpha-androst-2-en-17beta-ol. The 5alpha-androst-2-en-17beta-ol and -17-one profiles reflected cyclic ovarian activity with clear (10-20-fold) luteal phase increases. Furthermore, measurements of both compounds were correlated positively with the concentration of urinary pregnanetriol and indicated cycle duration (15.1 +/- 1.2 weeks) similar to that obtained from pregnanetriol measurements (15.2 +/- 1.6 weeks). The results demonstrate the presence of two luteal phase-specific steroidal volatile compounds in elephant urine. One of the substances, 5alpha-androst-2-en-17-one, has been demonstrated in human axillary bacterial isolates. The measurement of both volatile substances in elephant urine can be used for rapid detection of the stage of the ovarian cycle, as the analysis can be completed within 2 h.  (+info)

This is a nonrandomized (individuals will not be assigned by chance to study treatments), open-label (individuals will know the identity of study treatments), long-term safety follow-up study of abiraterone acetate in approximately 300 patients from other completed abiraterone acetate clinical studies. Patients must have received at least 3 months of treatment with abiraterone acetate and a low-dose corticosteroid and, based on investigator assessment, may benefit from continued treatment. This study will consist of a screening period followed by open-label treatment of continued abiraterone acetate access. The patients will continue with the same abiraterone acetate and low-dose corticosteroid dosing regimen they were receiving in the previous abiraterone acetate clinical study until the investigator determines that the patient is no longer receiving benefit or the sponsor terminates the study. Patients can be withdrawn from the study if an alternative access (eg, patient-assistance program or ...
Abiraterone acetate is a steroidal irreversible inhibitor of CYP17 (17α hydroxylase/C17, 20-lyase), blocking 2 important enzymatic activities in the synthesis of testosterone. The goal of this study is to compare the clinical benefit of abiraterone acetate plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer (CRPC) who have failed one or two chemotherapy regimens, one of which contains docetaxel. All patients involved in the study will be randomized (assigned by chance) into one of two arms and will not know what study drug is being given to them. Study drug randomization allocation will be 2:1 (abiraterone acetate: placebo). The study will be conducted in the United States, Canada, Australia, and the EU. The study will consist of screening, treatment, and follow-up. In this study, patients will receive study treatment (abiraterone acetate or placebo) plus prednisone until progression of clinical disease. Follow-up will continue until ...
Drugs and Targets FDA approves abiraterone acetate in combination with prednisone for high-risk metastatic castration-sensitive prostate cancer. FDA approved abiraterone acetate (Zytiga) tablets in combination with prednisone for metastatic high-risk castration-sensitive prostate cancer (CSPC). The drug is sponsored by Janssen Biotech Inc.. FDA initially approved abiraterone acetate with prednisone in 2011 for patients with metastatic castration-resistant prostate cancer (CRPC) who had received prior chemotherapy, and expanded the indication in 2012 for patients with metastatic CRPC. The latest approval was based on LATITUDE (NCT01715285), a placebo controlled international clinical trial that randomized 1,199 patients with metastatic high-risk CSPC. Patients received either abiraterone acetate, 1,000 mg orally once daily with prednisone 5 mg once daily (n=597), or placebos orally once daily (n=602). Patients in both arms received a gonadotropin releasing hormone or had a bilateral orchiectomy. ...
TY - JOUR. T1 - Quantitation of the anticancer drug abiraterone and its metabolite Δ(4)-abiraterone in human plasma using high-resolution mass spectrometry. AU - Bhatnagar, Atul. AU - McKay, Matthew J.. AU - Crumbaker, Megan. AU - Ahire, Ketan. AU - Karuso, Peter. AU - Gurney, Howard. AU - Molloy, Mark P.. PY - 2018/5/30. Y1 - 2018/5/30. N2 - Abiraterone acetate is administered as a prodrug to patients with metastatic, castration-resistant prostate cancer (mCRPC) and is readily metabolized into the potent 17a-hydroxylase/17,20-lyase (CYP17) enzyme inhibitor and androgen receptor inhibitor abiraterone and Δ(4)-abiraterone (D4A), respectively. To investigate pharmacokinetic variability in abiraterone acetate metabolism we developed highly sensitive liquid chromatography/mass spectrometry (LC/MS) assays for the simultaneous quantitation of abiraterone and D4A in human plasma using high-resolution mass spectrometry (HRMS) on an Orbitrap mass spectrometer. This study demonstrates the quantitative ...
Treatment of patients with progressive, castration-resistant prostate cancer (CRPC) with abiraterone in combination with prednisone leads to an increase in progression-free and overall survival pre- and post docetaxel as evidenced in two large, phase-III trials (COU-AA-301 [1], COU-AA-302 [2, 3]). Inclusion of patients in both phase-III and former trials required continuation of medical castration with luteinizing hormone-releasing hormone (LHRH) therapy in patients who had not undergone prior surgical castration. Therefore, the label on abiraterone (Zytiga®) contains advice to continue LHRH therapy during treatment with it [4]. However, in medically castrated men treated with abiraterone while continuing on LHRH therapy, testosterone further decreased rapidly to undetectable levels [5]. This potential of abiraterone to achieve even a more complete androgen deprivation than LHRH therapy alone appeals to speculation as to whether abiraterone may achieve and maintain testosterone deprivation at ...
99%), and is metabolised in the liver by CYP3A4 and SULT2A1 to inactive metabolites. The drug is excreted in feces (~88%) and urine (~5%), and has a terminal half-life of 12 ± 5 hours. Abiraterone acetate, also known as 17-(3-pyridinyl)androsta-5,16-dien-3β-ol acetate, is a synthetic androstane steroid and a derivative of androstadienol (androsta-5,16-dien-3β-ol), an endogenous androstane pheromone. It is specifically a derivative of androstadienol with a pyridine ring at the C17 position and an acetate ester attached to the C3β hydroxyl group. Abiraterone acetate is the C3β acetate ester of abiraterone. In the early 1990s, Mike Jarman, Elaine Barrie, and Gerry Potter of the Cancer Research UK Centre for Cancer Therapeutics in the Institute of Cancer Research in London set out to develop drug treatments for prostate cancer. Starting from the drug ketoconazole, they developed abiraterone, filing a patent in 1993 and publishing the first paper describing it the following year. Rights for ...
The results of the in vitro studies demonstrated that abiraterone acetate, abiraterone, and its major metabolites, abiraterone sulfate and abiraterone sulfate N-oxide, were inhibitors of CYP2C8 activity in human liver microsomes. Of these, abiraterone sulfate exhibited the most potent CYP2C8 inhibitory activity. Although not compared in the same assay, the data suggest that abiraterone sulfate is at least 10-fold more potent than abiraterone and its prodrug as a CYP2C8 inhibitor. Abiraterone acetate and abiraterone sulfate were predicted to have Ki values (inhibition constant = 0.5 × IC50) below 1 µM, which suggest high in vitro potency to cause in vivo drug interaction of at least two-fold (Obach et al., 2005). In a previous study, Cmax of abiraterone, abiraterone sulfate, and N-oxide abiraterone sulfate were reported to be approximately 0.37 µM, 25 µM, and 9.2 µM, respectively, after a single-dose administration of 1000 mg of abiraterone acetate to healthy volunteers (Bernard et al., ...
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer Academic Article ...
Boc Sciences offers cas 154229-18-2 Abiraterone acetate in bulk,please inquire us to get a quote for 154229-18-2 Abiraterone acetate.
Abiraterone acetate is the generic name for the trade name drug Zytiga®. Buy Abiraterone Acetate - instructions for use, price, analogues, generic
Abiraterone acetate (INN, USAN, BAN, JAN) (brand names Zytiga, Abiratas, Abretone, Abirapro) is a steroidal CYP17A1 inhibitor and by extension androgen synthesis inhibitor which is used in combination with prednisone in metastatic castration-resistant prostate cancer (mCRPC; previously called hormone-resistant or hormone-refractory prostate cancer) - i.e., prostate cancer not responding to androgen deprivation or treatment with androgen receptor antagonists.Wikipedia] A SNP in the CYP17A1 gene, rs2486758, has been reported (in a small study) to potentially indicate mCRPC patients responding better to AA/P therapy. ...
The STAMPEDE trial offers a direct, randomised, comparative analysis of two new standards for patients with hormone naive prostate cancer. This comparison was possible only because of the novel platform design of this protocol. Failure-free and progression-free survival clearly favoured SOC+abiraterone+prednisone, and with less certainty, metastasis-free survival favoured SOC+abiraterone+prednisone. However, the design means that abiraterone was given to progression whereas docetaxel was given as short course at start of therapy, meaning docetaxel patients had more salvage options at relapse, including docetaxel rechallenge. This explains the discrepancy between failure and progression-free survival favouring abiraterone but with no ultimate difference seen on overall or cause-specific survival. The proportion of patients having at least one "severe" toxicity was similar between the arms but the type of toxicities was quite different.. These data will help clinicians and patients to choose ...
There are emerging data regarding the therapeutic benefit of enzalutamide (ENZ) in the treatment of patients with castration-resistant prostate cancer (CRPC) pretreated with docetaxel and abiraterone acetate. To systematically evaluate the evidence regarding the efficacy of ENZ after docetaxel and abiraterone acetate treatment in CRPC, we performed a pooled analysis of all available studies. Studies that enrolled CRPC patients treated with ENZ after docetaxel and abiraterone acetate treatment were identified using PubMed, Web of Science, SCOPUS, The Cochrane Register of Controlled Trials, and EMBASE. A systematic review was conducted to calculate the pooled response rate (RR) and the 95% confidence interval (CI). Pooled median progression-free survival (PFS) and overall survival (OS), weighted on the number of patients of each of the selected trials, were also calculated. We tested for significant heterogeneity using the Cochran χ(2) test and the I(2) index. Ten publications were selected for ...
Growing evidence from clinical trials of the next-generation androgen receptor (AR) pathway inhibitors abiraterone acetate (AA) and MDV3100 suggests that both c...
The purpose of this study is to assess the safety and efficacy in Korea or Taiwan of oral abiraterone acetate and oral prednisolone in men with metastat
Abiraterone acetate is a prodrug of abiraterone, a selective androgen biosynthesis inhibitor that blocks cytochrome P450 17A1 (CYP17A1) and suppresses androgen and estrogen synthesis (1, 2). Used in combination with prednisone, abiraterone acetate is now approved for use in men with metastatic castration-resistant prostate cancer (mCRPC) in both the pre- and post-chemotherapy-treated settings based on demonstrated survival benefit. A review of the outcomes in these populations shows that the response in individual patients ranged from prolonged and durable to none at all, suggesting the presence of molecular alterations in tumors that predict for response. This finding, coupled with the recent approval of several other effective treatments for mCRPC, has highlighted the urgent need for predictive biomarkers that enrich for patient subpopulations in which treatment has a significant effect on clinically meaningful benefits. These associations are best demonstrated in the setting of randomized ...
This page contains brief information about abiraterone acetate and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
Michalski J, Sartor O, Parker C, et al. Radium-223 dichloride (Ra-223) impact on skeletal-related events, external-beam radiotherapy (EBRT), and pain in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Updated results from the phase III ALSYMPCA trial. Proceedings of the 55th Annual Meeting of the American Society of Radiation Oncology. International Journal of Radiation Oncology Biology Physics. 2013; 87(2): S108-S109. Abstract 265.. Smith MR, Saad F, Coleman R et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. Early online publication November 16, 2011.. Basch E, Autio K, Ryan CJ, et al: Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. The Lancet Oncology. 2013; 14(12):1193-1199.. Beer TM, ...
Purpose: Abiraterone improves the overall survival of men with metastatic castration-resistant prostate cancer. However, de novo or adaptive resistance to abiraterone limits its activity. Rational combinations of drugs with different mechanisms of action that overcome resistance mechanisms may improve the efficacy of therapy. To that end, we studied the molecular and phenotypic effects of the combination of cabozantinib plus abiraterone.. Experimental Design: Three prostate cancer cell lines were used to interrogate the in vitro molecular and antiproliferative effects of the single agents and combination of cabozantinib and abiraterone. The in vivo impact of the combination was assessed using the LAPC4-CR xenograft mouse model.. Results: In vitro proliferation studies demonstrated single-agent doses between 2 μmol/L and 10 μmol/L for abiraterone and cabozantinib inhibit prostate cancer cell proliferation in a dose-dependent manner, and the anticancer activity of abiraterone is enhanced when ...
The US Food and Drug Administration (FDA) today gave the green light for abiraterone acetate to be used in combination with prednisone for the treatment of "castration-resistant" prostate cancer in patients who have received prior docetaxel chemotherapy. "Todays announcement marks the culmination of two decades of work at the ICR to design and develop this drug," ICR Chief Executive Professor Alan Ashworth says. "This very significant achievement underlines the importance of drug discovery work in the not-for-profit sector." Abiraterone acetate was invented by Professor Mike Jarman and his colleagues in what is now the Cancer Research UK Cancer Therapeutics Unit at the ICR in Sutton, south of London. Prostate cancer cells need the male hormone testosterone to grow, so the team set out to design a drug that would cut off the source of testosterone. The ICR continued research on abiraterone acetate with The Royal Marsden Hospital after licensing the drug to Ortho Biotech Oncology Research & ...
The FDA announced the approval of Zytiga (abiraterone acetate), made by J&J subsidiary Janssen Biotech, for men with castration-resistant prostate cancer that has spread to other parts of the body, for use prior to receiving chemotherapy. The drug was already approved for castration-resistant prostate cancer in men who had already undergone chemotherapy treatment.. In castration-resistant prostate cancer, the cancer cells continue to grow even when men have undergone drug treatment or surgery to block testosterone, which stimulates the growth.. Todays approval demonstrates the benefit of further evaluation a drug in an earlier disease setting and provides patients and healthcare providers the option of using Zytiga earlier in the course of treatment, FDA Office of Oncology Drug Products director Richard Pazdur said.. ...
ORLANDO -- The investigational drug abiraterone acetate significantly improved outcomes in metastatic castrate-resistant prostate cancer in virtually every study-defined patient subgroup, researchers
Abiraterone acetate (INN, USAN, BAN, JAN) (brand names Zytiga, Abiratas, Abretone, Abirapro) is a steroidal antiandrogen, specifically an androgen synthesis inhibitor, used in combination with prednisone in metastatic castration-resistant prostate cancer (formerly hormone-resistant or hormone-refractory prostate cancer) - i.e., prostate cancer not responding to androgen deprivation or treatment with androgen receptor antagonists. It is a prodrug to the active agent abiraterone, and is marketed under the trade name Zytiga.. ...
Although one patient with recurrent ovarian cancer achieved complete response, the first trial of abiraterone conducted in ovarian cancer was halted early due to low response, according to results from the CORAL phase 2 trial.
Twenty-seven pts have been enrolled, 17 were previously treated with ketoconazole. Median baseline PSA and testosterone levels are 24.6 ng/mL and 5.5 ng/dL, respectively. PK data is available from 6 pts at 250 mg (3 fasted, 3 fed), 9 at 500 mg (6 fasted, 3 fed), 6 at 750 mg (3 fasted, 3 fed) as well as in 6 pts at the 1000 mg dose (fasted only). No abiraterone acetate was detectable, suggesting complete conversion to abiraterone. Maximum drug concentration (Cmax) was achieved within 2.1 hours irrespective of dose or fed vs fasted state (p=0.213). At the 500 and 750 mg but not 250 mg doses a significant increase in Cmax and AUC (p=0.010) was observed in the fed pts (a 2-, 5-fold increase at 500mg and 750 mg respectively). The mean terminal t 1/2 was comparable in the fed and fasted groups at all doses (approximately 7-8 hours). Administration of abiraterone acetate with food resulted in lower interpatient variability (up to 2 fold vs 7 fold differences in Cmax and AUC) and a more linear ...
Many Australian men die from prostate cancer every year, most from advanced stages in the hormone resistant form. Abiraterone acetate (Zytiga) is a new proven medication that can prolong life and reduce pain in advanced prostate cancer sufferers. It has been shown to delay progression of the incurable hormone-refractory form of the cancer for months, and even years. The trouble is the drug costs around $3,500 per month.. The Pharmaceutical Benefits Scheme (PBS) does not cover the cost of Zytiga for these patients unless they first endure chemotherapy and its unpleasant side-effects. Only when this remedy fails might they qualify. As a result they are condemned to more pain and an earlier death than they should be, all because of cost-cutting by government authorities. This is discrimination based on type of disease and is very unfair.. The bottom line is this drug is given earlier it will increase survival time, reduce suffering and delay the need for chemotherapy. Therefore these excluded ...
Cogent evidence points to the involvement of neurosteroids in the regulation of dopamine (DA) neurotransmission and signaling, yet the neurobiological bases of this link remain poorly understood. We previously showed that inhibition of 5α-reductase (5αR), a key neurosteroidogenic enzyme, attenuates the sensorimotor gating deficits induced by DA receptor activation, as measured by the prepulse inhibition (PPI) of the acoustic startle reflex. To extend these findings, the present study was aimed at the assessment of the role of other key neurosteroidogenic enzymes in PPI, such as 17α-hydroxylase/C17,20 lyase (CYP17A1), 3α- and 3β-hydroxysteroid dehydrogenase (HSD), in Sprague-Dawley rats. The PPI deficits induced by the DAergic non-selective agonist apomorphine (APO, 0.25 mg/kg, SC) were dose-dependently attenuated by the selective CYP17A1 inhibitor abiraterone (ABI, 10-50 mg/kg, IP) in a fashion akin to that of the 5αR inhibitor finasteride (FIN, 100 mg/kg, IP). These systemic effects were ...
The goal of this clinical research study is to find out how treatment with abiraterone acetate in combination with prednisone and a Luteinizing Hormone-
American Health & Drug Benefits® examines drug and other healthcare intervention value from the separate and unified vantage points of each stakeholder group to the process: payers, purchasers, providers, patients, manufacturers, regulators, distributors, and evaluators. Directly or indirectly, all parties to healthcare benefits influence policy and demand satisfaction of their interests.
Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.. ...
Background: ABIraterone (ABI) is a CYP17-lyase inhibitor, while ENZalutimide (ENZ) is an androgen receptor (AR) antagonist that inhibits nuclear translocation. Changes in serum cytokines have been noted in patients (pts) receiving docetaxel for metastatic castration-resistant prostate cancer (mCPRC) therapy (Mahon KL et al Br J Cancer 2015). We postulate that ABI and ENZ may also have a complex effect on cytokine profile.. Methods: In a prospective trial in mCPRC pts, ABI or ENZ was given according to physician preference. Blood was drawn at baseline, 4 weeks, 8 weeks, 12 weeks and at the time of progressive disease (PD). Plasma was separated from patients blood using Vacutainer CPT tubes (BD) within 2 hours after collection by centrifuging at 1800×g for 20 min at room temperature and stored in -80°c. Plasma samples were analyzed for 30 human cytokines and chemokines using Luminex FLEXMAP 3D system. Trends in serum cytokine profile were analyzed by supervised clustering, with segregation ...
Ando, Hikari and Williams, Carl and Robert M., Angus and Thornton, Everard W. and Chakrabarti, Biswajit and Cousins, Rosanna and Piggin, Lucy H. and Young, Carolyn A. (2014) Why dont they accept Non-Invasive Ventilation? : Insight into the interpersonal perspectives of patients with MND. British Journal of Health Psychology, 20. pp. 341-359. Ando, Hikari and Cousins, Rosanna and Young, Carolyn (2014) Achieving saturation in thematic analysis: development and refinement of a codebook. Comprehensive Psychology, 3. Article 4. ISSN ISSN 2165-2228 ...
Abiraterone (Abi) acetate (AA) is a prodrug of Abi, a CYP17A1 inhibitor used to treat patients with advanced prostate cancer. Abi is a selective steroidal inhibitor that blocks the biosynthesis of androgens. It undergoes extensive biotransformation by steroid pathways, leading to the formation of pharmacologically active Δ4-Abi (D4A) and 5α-Abi. This study aimed to characterize the glucuronidation pathway of Abi and its two active metabolites. We show that Abi, its metabolites, and another steroidal inhibitor galeterone (Gal) undergo secondary metabolism to form glucuronides (G) in human liver microsomes with minor formation by intestine and kidney microsomal preparations. The potential clinical relevance of this pathway is supported by the detection by liquid chromatography-tandem mass spectrometry of Abi-G, D4A-G, and 5α-Abi-G in patients under AA therapy. A screening of UGT enzymes reveals that UGT1A4 is the main enzyme involved. This is supported by inhibition experiments using a ...
Abiraterone | CYP17A1 inhibitor | CB 7598 | CB7598 | CAS [154229-19-3] | Axon 1873 | Axon Ligand™ with >100% purity available from supplier Axon Medchem, prime source of life science reagents for your research
ZYTIGA (Abiraterone) drug information & product resources from MPR including dosage information, educational materials, & patient assistance.
The presence of ≥ 5 circulating tumor cells (CTCs) heralded a worse prognosis among the 1,195 patients enrolled in the phase III study of abiraterone acetate (Zytiga) plus prednisone postdocetaxel.4 Circulating tumor cells were counted at baseline and periodically posttreatment. Conversion from , 5 CTCs per 7.5 mL to ≥ 5 was predictive of overall survival, and elevated CTCs correlated with an attenuation of treatment effect. Conversion was significantly more likely in the abiraterone arm: 48% by week 12 vs 17% with placebo (P , .0001); median overall survival was 22 vs 10 months, respectively.. "This was a large study with ambitious goals, but it was basically negative. It was unable to show that circulating tumor cells could substitute for overall survival in clinical trials," Dr. Oh noted. "In the multivariate analysis, baseline lactate dehydrogenase remained as powerful a prognostic factor as CTCs (P , .0001), and it is a 60-year-old biomarker that costs $40. PSA level was not prognostic, ...
Quote: Originally Posted by MHarris Higher body fat seems to correlate with higher natural androstenol . People tend to be at ease and sometimes very candid around larger people, which is exactly wha
The success of three new drugs (Abiraterone, Jevtana and Provenge) for castration-resistant prostate cancer (CRPC) this year, each targeting different pathways, and all showing an overall survival benefit, has raised the bar for those dreaming to join the club. There is at least one riding the popularity vote, MDV3100, which may complete phase 3 next year. Still, many struggle and plough through phase 1 and 2. One way to understand, what may make some of them unique - and the reason they may evolve into serious competition one day - is to lay them out in separate classes or targets. This is what I have done below. ...
Caribaeohypnum es un género monotípico confinado a las tierras altas tropicales. Fue ubicado previamente en Hypnum y Stereodon. Mientras comparte con Hypnum las hojas falcado-secundas, difiere de este género en el hábito más grande, pliegues fuertes extendiéndose bien arriba de la base de la hoja, particularmente notables en seco, y células alares irregularmente rectangulares fuertemente porosas y con paredes gruesas, excavadas. Los esporofitos en ambos géneros son aparentemente raros; en Caribaeohypnum los dientes del exostoma son papilosos a todo lo largo, estriado-papilosos abajo, la membrana basal es algo baja, con segmentos levemente plegados y no perforados, con cilios rudimentarios o ausentes. En Hypnum los dientes son estriados transversalmente abajo, y sólo papilosos distalmente, la membrana basal es alta, con segmentos plegados y perforados, con 1-3 cilios. Los esporofitos de Caribaeohypnum son desconocidos en los Andes Tropicales, la descripción se basa en Ando e Higuchi ...
70% off! - From the beautiful Dozing Tea Seller, to the striking The Wave from the series 100 Views of the Provinces - handmade oil painting reproductions of all of (after) Hiroshige, Ando or Utagawas most popular paintings are available at 1st-Art-Gallery.com. Always custom made on premium grade canvas by European artists.
Clinical trials in cancer generally measure the success of a new drug based on whether it increases "overall survival", in other words whether it keeps patients in the test group alive for longer than a control group. However, this method means researchers and regulators need to wait a long time before they can conclude that a new drug is benefiting patients - generally many months or even years.. As part of a Phase III trial for a new prostate cancer drug called abiraterone acetate, scientists at The Institute of Cancer Research (ICR) and The Royal Marsden along with international collaborators investigated whether the level of Circulating Tumour Cells (CTCs) in patients blood was linked to their subsequent survival. CTCs are cancer cells that have broken away from a tumour and entered the blood stream.. Scientists analysed blood from almost 1,000 patients with advanced prostate cancer, measuring the number of CTCs before treatment and then at four, eight and twelve weeks after starting ...
Abiraterone and enzalutamide are now listed in the interaction checker as cancer drugs and interactions can be found for all the comedications. • Abiraterone (Zytiga®) is an androgen biosynthesis inhibitor and is indicated for the treatment of prostatic neoplasms ...
Treatment with the drug used in combination with prednisone resulted in significant delays in most measures of pain progression and decline.
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites ...
中国古典料理への誘い--『斉民要術(せいみんようじゅつ)』から「芋子酸〔カク〕法(うしさんかくほう)」と「膏環(こうかん)」の作り方 (2005 ...
Fu, Xiao wei/ 木村 正彦/ 井上 真/ 伊賀 三佐子/ 長谷川 清/ 石岡 千寛/ 安田 謙二/ 宮崎 康二/ Tomotsuka, Yoshito/ Tanowaki, Tetsuo/ Takagi, Junji/ Ito, Toshio/ 楫野 恭久/ Ando, Yukinori/ 山口 清次/ ...
Silicon-containing Polymers: The Science and Technology of their Synthesis and Applications, D. Jones, W. Ando, J. Chojnowski, Eds., Kluwer Academic Publishers, Dordrecht, The Netherlands, 2000, pp. 461-498 ...
|p sourcefile=api/System.Buffers.ReadOnlySequence-1.Slice.yml sourcestartlinenumber=1 jsonPath=/members/0/summary||span data-ttu-id=e039a-142|Forma uma fatia do |xref data-throw-if-not-resolved=true uid=System.Buffers.ReadOnlySequence`1||/xref| atual, começando em um índice especificado e continuando até o final da sequência somente leitura.|/span||span class=sxs-lookup||span data-stu-id=e039a-142|Forms a slice out of the current |xref data-throw-if-not-resolved=true uid=System.Buffers.ReadOnlySequence`1||/xref|, beginning at a specified index and continuing to the end of the read-only sequence.|/span||/span||/p|
Espuny-Camacho I, Arranz AM, Fiers M, Snellinx A, Ando K, Munck S, Bonnefont J, Lambot L, Corthout N, Omodho L, Vanden Eynden E, et al ...
Corsair introduced the RMi series at Computex 2015, and it offers some major upgrades compared to the previous RM line. Today, we will evaluate the strongest RMi unit with 1 kW capacity in order to figure out how it does against its predecessor and all other competing offers in its category.
Looking for online definition of abiraterone in the Medical Dictionary? abiraterone explanation free. What is abiraterone? Meaning of abiraterone medical term. What does abiraterone mean?
Apalutamide with or without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients with High-Risk Prostate Cancer Undergoing Surgery
Paris (France) and Lund (Sweden), 3 October 2012 - Ipsen (Euronext: IPN; ADR: IPSEY) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced the initiation of a new phase II proof of concept clinical trial, evaluating the activity of tasquinimod in advanced metastatic castrate resistant prostate cancer patients. The study aims at establishing the clinical efficacy of tasquinimod used as maintenance therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC) who have not progressed after a first line docetaxel based chemotherapy. Karim Fizazi, Head of the Cancer Medicine Department of the Institut Gustave Roussy (IGR) in France and Principal investigator of the study said:"In current clinical practice, metastatic castrate-resistant prostate cancer patients with non-progressive disease after docetaxel treatment are not proposed any medication as no reference/standard treatment exists. These patients remain untreated until disease progression. Prolongation of the response to ...
Characterization of genes linked to bone metastasis is critical for identification of novel prognostic or predictive biomarkers and potential therapeutic targets in metastatic castrate-resistant prostate cancer (mCRPC). Although bone marrow core biopsies (BMBx) can be obtained for gene profiling, the procedure itself is invasive and uncommon practice in mCRPC patients. Conversely, circulating tumor cells (CTCs), which are likely to stem from bone metastases, can be isolated from blood. The goals of this exploratory study were to establish a sensitive methodology to analyze gene expression in BMBx and CTCs, and to determine whether the presence or absence of detectable gene expression is concordant in matching samples from mCRPC patients. The CellSearch® platform was used to enrich and enumerate CTCs. Low numbers of PC3 prostate cancer (PCa) cells were spiked into normal blood to assess cell recovery rate. RNA extracted from recovered PC3 cells was amplified using an Eberwine-based procedure to obtain
Kim N. Chi, MD, of BC Cancer, discusses updated results from a phase II study of cabazitaxel vs abiraterone or enzalutamide in patients with poor-prognosis metastatic castration-resistant prostate cancer (Abstract 5003).. ...
References. 1. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration- Resistant Prostate Cancer. Eur Urol. 2014;65:467-79.. 2. Cookson MS, Roth BJ, Dahm P, Engstrom C, Freedland SJ, Hussain M, et al. Castration-resistant prostate cancer: AUA guideline. 2013.. 3. NCCN. NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer. 2014.. 4. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13:983-92.. 5. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138-48.. 6. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, ...
Excerpt:. "In the phase III CA184-095trial reported in the Journal of Clinical Oncology, Tomasz M. Beer, MD, FACP, of the Knight Cancer Institute, Oregon Health and Science University, and colleagues found that ipilimumab (Yervoy) did not increase overall survival vs placebo in men with asymptomatic or minimally symptomatic chemotherapy-naive metastatic castration-resistant prostate cancer without visceral metastases. Ipilimumab was associated with prolonged progression-free survival and a higher prostate-specific antigen (PSA) response rate.". Go to full article.. If youre wondering whether this story applies to your own cancer case or a loved ones, we invite you to use our ASK Cancer Commons service.. ...
1 http://www.auanet.org/education/guidelines/prostate-cancer.cfm. 2 Basch E, Autio K, Ryan CJ, et al: Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. The Lancet Oncology. 2013; 14(12):1193-1199.. 3 Beer TM, Armstrong AJ, Sternberg CN, et al: Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): Results of phase III PREVAIL study. Presented at the 2014 Genitourinary Cancers Symposium. Journal of Clinical Oncology. 2014; 32 (supplement 4; abstract LBA1).. 4 Nelson J, Banato A, Battistini B, Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer2003;3(2):110-116.. 5 Scher HI, Fizazi K, Saad F et al: Increased survival with enzalutamide in prostate cancer after chemotherapy. N Eng J Med 2012; 367: 1187.. 6 de Bono JS, Logothetis CJ, Molina A et al: Abiraterone and increased survival in metastatic prostate ...
This study is comparing the efficacy and tolerability of enzalutamide + abiraterone acetate + prednisone versus enzalutamide in patients with
Bayer HealthCare and Orion Corporation, a pharmaceutical company based in Espoo, Finland, have begun to enroll patients in a Phase III trial with ODM-201, an investigational novel oral androgen receptor (AR) inhibitor in clinical development for the treatment of patients with prostate cancer. The study, called ARAMIS, evaluates ODM-201 in men with castration-resistant prostate cancer […]. ...
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended darolutamide, an androgen receptor inhibitor (ARi), for marketing authorization in the European Union (EU).. The compound, which is developed jointly by Orion Corporation and Bayer, is recommended for the treatment of men with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease. The final decision of the European Commission on the marketing authorisation is expected in the coming months. The androgen receptor inhibitor (ARi) is already approved in the in the U.S., Brazil and Japan and filings in other regions are underway or planned by Bayer.. Bayer is responsible for global commercialization of darolutamide, with a co-promotion of Bayer and Orion in certain European markets, e.g. in France, Germany, Italy, Spain, the UK, Scandinavia and Finland.. The CHMP recommendation is based on the results of the Phase III ARAMIS ...
Clinicians are challenged with a multitude of treatment options for patients with castration-resistant prostate cancer (CRPC). To assist in clinical decision-making, six index patients were developed representing the most common clinical scenarios that are encountered in clinical practice. With these patients in mind, guideline statements were developed to provide a rational basis for treatment based on currently available published data.
by NewsRx editors, research stated, "Prostate-specific membrane antigen (PSMA) is a promising target for the diagnosis of and therapy for metastatic castration-resistant prostate cancer (mCRPC). The aim of this study was to measure overall-survival (OS) in mCRPC patients who received either abiraterone or enzalutamide prior to PSMA therapy.". Our news journalists obtained a quote from the research from University Hospital Bonn, "The second aim of this study was to analyse the predictors of OS according to different pre-therapeutic parameters and also the responses to the first cycle of radioligand therapy (RLT) base on PSA level. Patients with mCRPC and a history of therapy with either abiraterone or enzalutamide or both, were included in this study. Different laboratory tests and pre-therapeutic parameters have been included into the analysis. One-hundred patients received a total of 347 cycles of Lu-PSMA (median: three cycles). 69 patients showed a decline in PSA two months after the first ...
chemBlink provides information about CAS # 98319-26-7, Finasteride, N-(2-methyl-2-propyl)-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide, Proscar, molecular formula: C23H36N2O2.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. These forward-looking statements include, without limitation, statements related to the benefits to be derived from Cougars drug development programs, including the potential advantages of CB7630 and its potential for use in the treatment of CRPC and in second-line hormone and chemotherapy treatment settings. Such statements involve risks and uncertainties that could cause Cougars actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially ...
PSA progression defined by a minimum of two rising PSA levels with an interval of ≥ 1 week between each determination. Patients who received an anti-androgen must have progression documented by a minimum of two rising PSA levels with an interval of ≥ 1 week between each determination such that at least the second of these rises is ≥ 4 weeks since last flutamide, bicalutamide or nilutamide.. The PSA value at the screening should be ≥ 2 µg/L (2 ng/mL) .. ...
Quality Muscle Building Steroids manufacturers & exporter - buy Natural Oral Muscle Gaining Steroids Abiraterone 154229-19-3 Pharmaceutical Grade from China manufacturer.
Androstenol -- There are two types of this compound, the alpha and beta isomers, each producing slightly different effects. The alpha and beta have nothing to do with the pheromone projecting an alpha aura. Both seem to cause chattiness and friendliness. It is also known to increase sexual appeal making it great for breaking the ice. The alpha isomer produces a friendly atmosphere which makes the user more approachable for women. Androstenol also creates an aura of youth and health, which can help to create a youthful perception for older people.Androstenol also creates a feeling of youthfullness and health which can be a sexual turn on for women. The primary reported response to Androstenol or Androstenol containing products has been an increase in chattiness and friendliness from both sexes, but as mentioned above it can increase sexual attractiveness as well. It has been referred to as an ice-breaker pheromone. If you find anything extra mentioning about Pheromones, do inform us. It is ...
https://doi.org/10.18632/oncotarget.16463 Francesco Morra, Francesco Merolla, Virginia Napolitano, Gennaro Ilardi, Caterina Miro, Simona Paladino, Stefania Staibano, Aniello Cerrato, Angela Celetti
H&O How common is resistance to abiraterone and enzalutamide in castration-resistant prostate cancer (CRPC)? ESA Approximately 15% to 25% of patients with CRPC do not respond to […]. ...
ISI Document Delivery No.: 132YQ Times Cited: 0 Cited Reference Count: 202 Horwich, A. Hugosson, J. de Reijke, T. Wiegel, T. Fizazi, K. Kataja, V. Abbott Pharmaceuticals; GlaxoSmithKline; Lilly Pharmaceuticals Dominik Berthold (advisory board role-Astellas, Sanofi, Janssen); Gedske Daugaard (advisory board role-Sanofi-Aventis, Janssen); David Dearnaley (reward for inventions for abiraterone o and advisory board role-Amgen, Takeda, Novartis, AstraZeneca, institution (ICR) receives royalties from the drug abiraterone and department has research collaboration with Algeta); Karim Fizazi (research and speakers bureau-Amgen, AstraZeneca, Bristol-Myers Squibb, Janssen, Astellas/Medivation, Novartis, Sanofi-Aventis, Dendreon, Bayer, Keocyt, Millennium-Takeda, Orion, Merck, Exelixis); Silke Gillessen (advisory board role-Millennium, Janssen, Sanofi); Alan Horwich (no personal conflicts, institution (ICR) receives royalties from the drug abiraterone and department has research collaboration with ...
continues to expect top-line data from COMET-1 and a second pivotal trial in mCRPC, COMET-2, in 2014. COMET-1 is a randomized, double-blind, placebo-controlled trial designed to enroll 960 patients with mCRPC who have previously been treated with docetaxel, abiraterone acetate and/or enzalutamide. All patients in the trial have bone metastases and there is no limit to the number or type of prior treatments. Patients are randomized 2:1 to receive cabozantinib (60 mg daily) or prednisone (5 mg twice daily). The trial is event-driven and has 90% power to detect a 25% reduction in the risk of death (HR = 0.75) at the time of final analysis, which requires 578 events. A single interim analysis after 387 events is also planned and will assess if the trial achieved its primary endpoint; it will not include a futility analysis. The secondary endpoint of the trial is bone scan response as assessed by an independent radiology facility (IRF). "Reaching the COMET-1 enrollment target is a significant ...
TUESDAY, Aug. 13, 2019 (HealthDay News) - Elderly prostate cancer patients with preexisting cardiovascular diseases (CVDs) using abiraterone acetate (AA) or enzalutamide (ENZ) have higher short-term mortality compared with their counterparts without CVDs, according to a study published online Aug. 13 in European Urology.. Grace Lu-Yao, Ph.D., M.P.H., from the Sidney Kimmel Cancer Center at Jefferson in Philadelphia, and colleagues examined the short-term outcomes of AA and ENZ in patients by preexisting CVDs in a population-based retrospective study.. The researchers found that 67 percent of the eligible patients (2,845 with AA and 1,031 with ENZ) had at least one preexisting CVD. Those with one or two preexisting CVDs had higher six-month mortality compared with those without preexisting CVDs (relative risk, 1.16; 95 percent confidence interval, 1.00 to 1.36); the risk was further increased among those with three or more preexisting CVDs (relative risk, 1.56; 95 percent confidence interval, ...
View Ando Aasas business profile as Oncotherapy, Physicist at Tartu University Hospital and see work history, affiliations and more.
Profile of participants and genotype distributions of 108 polymorphisms in a cross-sectional study of associations of genotypes with lifestyle and clinical factors: a project in the Japan Multi-Institutional Collaborative Cohort (J-MICC) Study., Wakai K, Hamajima N, Okada R, Naito M, Morita E, Hishida A, Kawai S, Nishio K, Yin G, Asai Y, Matsuo K, Hosono S, Ito H, Watanabe M, Kawase T, Suzuki T, Tajima K, Tanaka K, Higaki Y, Hara M, Imaizumi T, Taguchi N, Nakamura K, Nanri H, Sakamoto T, Horita M, Shinchi K, Kita Y, Turin TC, Rumana N, Matsui K, Miura K, Ueshima H, Takashima N, Nakamura Y, Suzuki S, Ando R, Hosono A, Imaeda N, Shibata K, Goto C, Hattori N, Fukatsu M, Yamada T, Tokudome S, Takezaki T, Niimura H, Hirasada K, Nakamura A, Tatebo M, Ogawa S, Tsunematsu N, Chiba S, Mikami H, Kono S, Ohnaka K, Takayanagi R, Watanabe Y, Ozaki E, Shigeta M, Kuriyama N, Yoshikawa A, Matsui D, Watanabe I, Inoue K, Ozasa K, Mitani S, Arisawa K, Uemura H, Hiyoshi M, Takami H, Yamaguchi M, Nakamoto M, Takeda ...
124 pts were included: 111 (89.5%) received docetaxel (Dx), 13 (10.5%) cabazitaxel (Cz) and 27 (21.8%) both. Fifty-seven (45.9%) tumors were TE+. Overall, no correlation between tumor TE expression and taxane benefit was observed in the whole population, or in the Dx or Cz group separately. However, in Dx-treated pts without prior A/E (N = 80, 72.1%), tumor TE+ correlated with lower PSA-PFS (median 8.6 vs 13.6 months; HR 1.7, p ≤ 0.05). No differences were observed in Dx treated pts with prior A/E (N = 31, 27.9%) according to tumor TE expression. In 44 pts, matched tumor and PBMC samples were available. Concordance between tumor an blood was 92.8% and 63.3% for pts with and without prior A/E, respectively. TE in blood was + in 1 (7%) pts with prior A/E and in 7 (23.3%) pts without prior A/E. As observed in FFPE samples, in patients without prior A/E to Dx (N = 28; 63.6%), blood TE+ correlated with lower PSA response (0% vs 61.9%, p ≤ 0.01) and reduced median PSA-PFS (3.34 vs 8.2 mM; HR 4.1 p ...
READ BOOK Arisa, Vol. 11 by Natsumi Ando. -,-,-,-,ONLINE BOOK Arisa, Vol. 11 by Natsumi Ando. -,-,-,-, DOWNLOAD BOOK Arisa, Vol. 11 by Natsumi Ando. Book description. I am still in awe that Midori, Arisas boyfriend, is the one who schemed and plotted all the terrible incidents that has taken place. He genuinely believes that he is carrying out the wishes of his girlfriend. Tsubasa, Arisas twin sister, demands for her side of the story. Arisa then explains that she and Midori share the same story where they were both essentially abandoned by their mother during their early childhoods. Through this connection, they both formed a romantic relationship. Midori did not know that Arisa created King time or so she thought. Her version of King time consisted of giving people advice and such. As time progresses and King time becomes more popular, people in her class began to demand for more such as test answers so that they can all pass. Tempted to do so, Arisa gets the test answers but she finds herself ...
Background/Aims Certain liver diseases have been associated with depletion of glutathione (GSH) the major antioxidant in liver. and attenuated mitochondrial damage accompanied with diminished hepatic steatosis; however abnormal liver biochemical tests hepatocytes death and hepatic oxidative stress persisted in the rescued mice. At age 50 days the liver from rescued mice started to display characteristics of fibrosis and at age 120 days macronodular cirrhosis was observed. Immunohistostaining for liver-specific markers and the expression profile of hepatic cytokines indicated that the repopulation of hepatocytes in the cirrhotic nodules involves the expansion of oval cells. Conclusions Replenishment of mitochondrial GSH and restoration of mitochondrial function by NAC prevent mortality caused by loss of hepatocyte GSH synthesis allowing the progression of steatosis to a chronic stage. Thus with NAC supplementation mice provide a model for the development of liver fibrosis and cirrhosis. ...
SelfDecode is a personalized health report service, which enables users to obtain detailed information and reports based on their genome. SelfDecode does not treat, diagnose or cure any conditions, but is for informational and educational purposes alone. ...
Piccinini, Filippo and Balassa, Tamás and Szkalisity, Ábel and Molnár, Csaba and Paavolainen, Lassi and Buzás, Krisztina and Horváth, Péter (2017) Advanced Cell Classifier: User-Friendly Machine-Learning-Based Software for Discovering Phenotypes in High-Content Imaging Data. CELL SYSTEMS, 4 (6). pp. 651-655. ISSN 2405-4712 Saeed, K. and Rahkama, V. and Eldfors, S. and Bychkov, D. and Mpindi, J. P. and Horváth, Péter (2017) Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer. EUROPEAN UROLOGY, 71 (3). pp. 319-327. ISSN 0302-2838 Caicedo, J. C. and Cooper, S. and Heigwer, F. and Warchal, S. and Qiu, P. and Molnár, Csaba and Horváth, Péter (2017) Data-analysis strategies for image-based cell profiling. NATURE METHODS, 14 (9). pp. 849-863. ISSN 1548-7091 Frismantas, V. and Dobay, M. P. and Rinaldi, A. and Tchinda, J. and Dunn, S. H. and Horváth, Péter (2017) Ex vivo drug response profiling detects recurrent sensitivity ...
Upon complete construction of the museum, a second phase consisting mainly of lodgings was designed to built on a hill behind the museum. A cable car takes us from the museum to the top of the hill. Leaving behind the station, we pass through a garden with a waterfall; we see a water garden at the bottom of an elliptical opening in the hill. The water reflects the sky framed by the ellipse. The guest rooms constructed around the elliptical garden afford beautiful views of the Inland Sea. This is a "detached palace" in a quiet world of its own.. Light and air, rendered extremely abstract, fill the interior spaces of Andos religious buildings and private houses. In this work, however, the landscape is quite specific. By enabling us to actually "feel" specific objects and phenomena in the landscape such as sunsets, the wake of a boat, cresting waves, silhouettes of distant islands and stormy skies, he creates spaces that restore to us our physicality and sensitivity.. ...
Zytiga: Abiraterone belongs to the class of medications called androgen biosynthesis inhibitors. It is taken along with low doses of prednisone to treat metastatic prostate cancer (cancer that has spread to other parts of the body) when other treatments have failed. It stops your body from making testosterone, a male hormone that is involved in the growth of prostate cancer.
MDV 3100 | AR antagonist | Enzalutamide | MDV3100 | CAS [915087-33-1] | Axon 1613 | Axon Ligand™ with >99% purity available from supplier Axon Medchem, prime source of life science reagents for your research
Learn about Xtandi (Enzalutamide Capsules) may treat, uses, dosage, side effects, drug interactions, warnings, patient labeling, reviews, and related medications.
PHERO - MAX mengandungi bahan pheromone sintetik bernama Androstenone, 5-alpha-an-drost-16-ene-one, androstenol, androsterone, estratetraenol dan androstadieno
Tem muita marca lançando produtos liberados para Low Po e No Poo, fique de olho nos lançamentos da Tutanat, Forever Liss, Inoar, Amend, Charming, Bothânico Hair, Skafe, Gota Dourada e a Crismas. Siga o Cabeleira em Pé e fique por dentro das Novidades.
Former world champion Miki Ando will once again be looking for redemption and Yukari Nakano, the fourth-place finisher at the world championships last Marc
Compară companiile 36 in location MEDIAŞ MEDEŞAN MARIA PERSOANĂ FIZICĂ AUTORIZATĂ, AGROCONSULT ANDO SRL, BLUE SERVICES SRL, BARBU MARIUS-GABRIEL ÎNTREPRINDERE...
After months I use V-Ray. After many experiments, we get the know-how, as is with the 3Ds Max itself (for years!). Many inveighs occurs, because, it seems that those programs insist on fight against us. Unless we reach the hit, soon (often, luckily).. Find one or another solution (a variety of parameters and its tests... ando so on...) until get the best for me.. As everybody (we + chaosgroup + third parts), Im working to provide many "apparatus" for each render engine (many -- I believe to be a good idea to use all of them, if possible to you) -- On certain case, we must use one, in another case, the second one.... The SCRIPTS and plugs are the true heroes.. Im replying about it after many time.. Thanks.. ...
The NLRA was enacted by Congress in 1935. It was hailed at the time and for many years after as the Magna Carta of America labor. Previously, employers had been free to spy on, interrogate, discipline, discharge, and blacklist union members. But in the 1930s workers began to organize militantly. A great strike wave in 1933 and 1934 included citywide general strikes and factory takeovers. Violent confrontations occurred between workers trying to form unions and the police and private security forces defending the interests of anti-union employers. Some historians believe that Congress adopted the NLRA primarily in the hopes of averting greater, possible revolutionary, labor unrest.. The NLRA guaranteed workers the right to join unions without fear of management reprisal. It created the National Labor Relations Board (NLRB) to enforce this right and prohibited employers from committing unfair labor practices that might discourage organizing or prevent workers from negotiating a union ...
BERKELEY, CA (UroToday.com) - Prostate cancer is the most common malignancy in men in the United States with an estimated 220 800 new cases and 27 540 deaths in 2015.[1] In 2004, two landmark trials, TAX 327 and SWOG 99-16, revealed an overall survival (OS) benefit in men with progressive metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel,[2, 3] however benefits remain limited. In recent years, agents such as abiraterone and enzalutamide have shown an OS benefit, similar to docetaxel, in the mCRPC population.[4, 5] Several agents that target angiogenesis have been combined with docetaxel in an attempt to improve OS, but unfortunately, the results of these trials have proved to be disappointing. Alternative approaches to targeting tumor vasculature and attempting combination therapies need further investigation. One such alternative approach is targeting CD105, which is involved in normal vascular development, is expressed on proliferating endothelial cells, and has ...
BACKGROUND: In the AFFIRM trial, enzalutamide significantly increased overall survival (OS) for men with metastatic castration-resistant prostate cancer (mCRPC) after chemotherapy versus placebo and significantly decreased prostate-specific antigen (PSA) levels. The goal of this post hoc analysis was to associate levels of PSA decline from baseline after enzalutamide with clinical outcomes in the postchemotherapy mCRPC setting. METHODS: Men in the AFFIRM trial (n = 1199) were grouped by maximal PSA decline in the first 90 days of treatment. Kaplan-Meier estimates evaluated the association of defined PSA changes from baseline with OS, progression-free survival (PFS), radiographic PFS (rPFS), and pain response. Each PSA decline category was assessed for OS surrogacy using Prentice criteria, proportion of treatment effect explained (PTE), and proportion of variation explained. RESULTS: Men treated with enzalutamide had improved OS (hazard ratio, 0.63; P , .001) and higher rates of PSA decline (odds ...
Androgen deprivation therapy (ADT) is the most preferred treatment for men with metastatic prostate cancer (PCa). However, the disease eventually progresses and develops resistance to ADT in majority of the patients, leading to the emergence of metastatic castration-resistant prostate cancer (mCRPC).
Background: Enzalutamide significantly prolonged the survival of men with metastatic castration-resistant prostate cancer (PCa) after docetaxel in the randomised, phase 3, double-blind, placebo-controlled, multinational Patients with Progressive Castration-Resistant Prostate Cancer Previously Treated with Docetaxel-Based Chemotherapy (AFFIRM) trial (NCT00974311). Prostate-specific antigen (PSA) is commonly used as a marker of PCa disease burden, and the relationship of baseline PSA level to consequent treatment effect is of clinical interest. Objective: Exploratory analysis to evaluate any differences in patient characteristics and efficacy outcomes by baseline PSA level in the AFFIRM trial. Design, setting, and participants: Post hoc subanalysis of all randomised patients (n = 1199) from the AFFIRM trial. Intervention: Participants were randomly assigned in a two-to-one ratio to receive oral enzalutamide 160 mg/d or placebo. Outcome measurements and statistical analysis: The major clinical ...
1 Sweeney C., et al. Impact on overall survival with chemohormonal therapy versus hormonal therapy for home-sensitivity newly metastatic prostate cancer: An ECOG-led phase III randomized trial. ASCO 2014; Abstract LBA2.. 2 Tannock I, de Wit R, Berry W, et al.Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer. New England Journal of Medicine. 2004; 351:1502-1512.. 3 Petrylak D, Tangen C, Hussain M, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. New England Journal of Medicine. 2004; 351:1513-1520.. 4 de Bono JS, Oudard S, Ozguroglu M et al: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet 2010; 376: 1147.. 5 Kantoff PW, Higano CS, Shore ND et al: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411.. 6 Basch E, Autio K, Ryan ...
TY - JOUR. T1 - Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. AU - Taplin, Mary Ellen. AU - Regan, Meredith M.. AU - Ko, Yoo Joung. AU - Bubley, Glenn J.. AU - Duggan, Stephen E.. AU - Werner, Lillian. AU - Beer, Tomasz M.. AU - Ryan, Christopher W.. AU - Mathew, Paul. AU - Tu, Shi Ming. AU - Denmeade, Samuel R. AU - Oh, William K.. AU - Sartor, Oliver. AU - Mantzoros, Christos S.. AU - Rittmaster, Roger. AU - Kantoff, Philip W.. AU - Balk, Steven P.. PY - 2009/11/15. Y1 - 2009/11/15. N2 - Purpose: Increasing evidence indicates that enhanced intratumoral androgen synthesis contributes to prostate cancer progression after androgen deprivation therapy. This phase II study was designed to assess responses to blocking multiple steps in androgen synthesis with inhibitors of CYP17A1 (ketoconazole) and type I and II 5α-reductases (dutasteride) in patients with castration-resistant prostate cancer ...
Men with advanced prostate cancer can now receive a new innovative treatment in the Sarah Bush Lincoln Regional Cancer Center. SBL is the only cancer center in the region to offer Xofigo® , a new type of targeted radiation therapy.. In May, the U.S. Food and Drug Administration (FDA) approved Xofigo® (radium 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones, but not to other organs. It is intended for men whose cancer has spread after receiving medical or surgical therapy to lower testosterone.. "Xofigo® is an important new treatment added to our robust nuclear therapeutics program," said Abdur R Shakir, MD, SBL Regional Cancer Center Medical Director. "While we provide the people of East Central Illinois with leading-edge treatments for a broad range of cancers, we are proud to play a significant role in the development and delivery of important new breakthrough treatments as part of the Regional Cancer ...
Background: Since androgen-androgen receptor (AR) axis is the main stream for development and progression of prostate cancer, androgen-deprivation therapy (ADT) is conducted as a first line hormonal therapy using medical castration, such as LH-RH agonists, LH-RH antagonist, and antiandrogen for advanced PCa. After an initial response to ADT, however, PCa eventually loses responsiveness to ADT and progresses into castration-resistant prostate cancer (CRPC). Prevention of the development of castration-resistant from hormone-naïve prostate cancer is an important issue in maintaining the quality of life of the patients. We explored the effect of 2-hydroxyflavanone on proliferation and androgen responsiveness using prostate cancer cell lines.. Materials and Methods: To investigate the effect of 2 -hydroxyflavanone on proliferation, prostate cancer cells were treated with 2-hydroxyflavanone. Androgen-responsiveness in LNCaP cells was confirmed by luciferase assay after transfection of luciferase ...

Advanced Search Results - Public Health Image Library(PHIL)Advanced Search Results - Public Health Image Library(PHIL)

Categories: Androstenols Image Types: Photo, Illustrations, Video, Color, Black&White, PublicDomain, CopyrightRestricted 1 ...
more infohttps://phil.cdc.gov/AdvancedSearchResults.aspx?Search=Androstenols&parentid=2795&catid=2796

HE3204 - Semantic ScholarHE3204 - Semantic Scholar

6668 Background: HE2100, androst-5-ene-3β,17β-diol, and HE3204 are naturally occurring and synthetic adrenal steroid hormones… (More) ...
more infohttps://www.semanticscholar.org/topic/HE3204/1294584

Xue JL, et al. Raising intact male pigs for meatXue JL, et al. Raising intact male pigs for meat

5[alpha]- and 5[beta]-androstenols also contribute to sex odor. Subsequently, 5[alpha]-androstenone, 5[alpha]-, and 5[beta]- ... androstenols were found in the testes,17,18 fat,4,19,20 submaxillary gland and saliva,14,18 and parotid gland21 of boars. ... androstenols.14 When a mature boar is aroused by the presence of an estrous female or an unfamiliar boar, he champs copious ...
more infohttps://www.aasv.org/jshap/issues/v5n4/v5n4p151.html

Janardan K Reddy - Research Output
     - Northwestern ScholarsJanardan K Reddy - Research Output - Northwestern Scholars

Klootwijk, E. D., Reichold, M., Helip-Wooley, A., Tolaymat, A., Broeker, C., Robinette, S. L., Reinders, J., Peindl, D., Renner, K., Eberhart, K., Assmann, N., Oefner, P. J., Dettmer, K., Sterner, C., Schroeder, J., Zorger, N., Witzgall, R., Reinhold, S. W., Stanescu, H. C., Bockenhauer, D. & 19 others, Jaureguiberry, G., Courtneidge, H., Hall, A. M., Wijeyesekera, A. D., Holmes, E., Nicholson, J. K., OBrien, K., Bernardini, I., Krasnewich, D. M., Arcos-Burgos, M., Izumi, Y., Nonoguchi, H., Jia, Y., Reddy, J. K., Ilyas, M., Unwin, R. J., Gahl, W. A., Warth, R. & Kleta, R., Jan 1 2014, In : New England Journal of Medicine. 370, 2, p. 129-138 10 p.. Research output: Contribution to journal › Article ...
more infohttps://www.scholars.northwestern.edu/en/persons/janardan-k-reddy/publications/

Anyone tried Liquid TrustAnyone tried Liquid Trust

But, Androstenols do break down into Androstenone on human skin. So, pig pheromone or not it, is found in humans and if it ... But, Androstenols do break down into Androstenone on human skin. So, pig pheromone or not it, is found in humans and if it ...
more infohttp://pherotruth.com/Thread-Anyone-tried-Liquid-Trust

Prasterone - Jenapharm - AdisInsightPrasterone - Jenapharm - AdisInsight

Class Androstenols; Hormonal replacements; Small molecules; Testosterone congeners * Mechanism of Action Protein synthesis ...
more infohttp://adisinsight.springer.com/drugs/800013237?error=cookies_not_supported&code=ff864ef6-10a6-4373-997a-828e03045387

Hologenome theory of evolution - WikipediaHologenome theory of evolution - Wikipedia

in 1990 indicating that essential mating pheromones, including androstenols, required activation by skin-associated microbial ...
more infohttps://en.wikipedia.org/wiki/Hologenome_theory_of_evolution

DeCS Ingl s+escopoDeCS Ingl s+escopo

Androstenols .. Hydroxyandrostenes .. Unsaturated androstanes which are substituted with one or more hydroxyl groups in any ... D04.210.500.054.079.429 Androstenols .. D04.210.500.054.079.429.625 Dehydroepiandrosterone .. D04.210.500.365 Estranes .. ...
more infohttp://trigramas.bireme.br/cgi-bin/mx/[email protected]?collection=DeCSxi&lang=i&minsim=0.30&maxrel=10&text=Norandrostenolone

DeCS Ingl s+escopoDeCS Ingl s+escopo

D04.210.500.054.079.429 Androstenols .. D04.210.500.054.079.429.824 Testosterone .. D04.210.500.054.079.429.824.664 ...
more infohttp://trigramas.bireme.br/cgi-bin/mx/[email protected]?collection=DeCSxi&lang=i&minsim=0.30&maxrel=10&text=Viridiplantae

Beta Androstanol (BANOL) DPGBeta Androstanol (BANOL) DPG

Human semen was examined for the presence of 16-androstenols, 16-androstenones and androgens. Extracts were analysed by gas ... The axillary skin levels of 3 alpha- and 3 beta-androstenols, androstadienol and, in 3 subjects, androstadienone exceeded those ... androstenols] were only found in small amounts (, 0.1 nmol/microliters) in a few subjects. In the second study, prior to ...
more infohttps://pheromonexs.com/pheromone-molecules-xs/pheromone-molecules-oils-dpg/beta-androstanol-banol-dpg.html

List of MeSH codes (D04) - WikipediaList of MeSH codes (D04) - Wikipedia

... androstenols MeSH D04.808.054.079.429.154 --- androstenediols MeSH D04.808.054.079.429.154.050 --- androstenediol MeSH D04.808. ...
more infohttps://en.wikipedia.org/wiki/List_of_MeSH_codes_(D04)

SALE! True Confessions - UNscented Pheromone Blend - for Men and Women -  Love Potion Magickal PerfumerieSALE! True Confessions - UNscented Pheromone Blend - for Men and Women - Love Potion Magickal Perfumerie

The much celebrated combination of Beta and Alpha Androstenols, which purportedly encourages approach-ability, chattiness, and ... The much celebrated combination of Beta and Alpha Androstenols, which purportedly encourages approach-ability, chattiness, and ...
more infohttps://luvpotionperfume.com/listing/518068914/sale-true-confessions-unscented

Hologenomics - Omics.orgHologenomics - Omics.org

Studies by Froebe et al.[12] in 1990 indicating that essential mating pheromones, including androstenols, required activation ...
more infohttps://omics.org/Hologenomics

LIST OF PHEROMONE BLENDS - Pheromone Arena - Perfume Chat and Trading PostLIST OF PHEROMONE BLENDS - Pheromone Arena - Perfume Chat and Trading Post

TRUE CONFESSIONS - (unisex) - The much celebrated combination of Beta and Alpha Androstenols, which purportedly encourage ...
more infohttp://lovepotion.invisionzone.com/topic/7966-list-of-pheromone-blends/?tab=comments

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate...Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate...

Androstenols. *abiraterone. Grant support. *G0501019/Medical Research Council/United Kingdom. *Cancer Research UK/United ...
more infohttps://www.ncbi.nlm.nih.gov/pubmed/18645193?dopt=Abstract

Abiraterone and increased survival in metastatic prostate cancer.  - PubMed - NCBIAbiraterone and increased survival in metastatic prostate cancer. - PubMed - NCBI

Androstenols/therapeutic use*. *Antineoplastic Combined Chemotherapy Protocols/adverse effects. *Antineoplastic Combined ...
more infohttps://www.ncbi.nlm.nih.gov/pubmed/21612468?dopt=Abstract

HE3286 - DrugBankHE3286 - DrugBank

Androstenols. *Cytochrome P-450 CYP3A Substrates. *Cytochrome P-450 CYP3A4 Substrates. *Cytochrome P-450 CYP3A4 Substrates ( ...
more infohttps://www.drugbank.ca/drugs/DB05212

Testosterone undecanoate - DrugBankTestosterone undecanoate - DrugBank

Androstenols. *BCRP/ABCG2 Substrates. *Cytochrome P-450 CYP2B6 Inducers. *Cytochrome P-450 CYP2B6 Substrates ...
more infohttps://www.drugbank.ca/drugs/DB13946

16-hydroxydehydroepiandrosterone sulfate
     Summary Report | CureHunter16-hydroxydehydroepiandrosterone sulfate Summary Report | CureHunter

16-hydroxydehydroepiandrosterone sulfate: RN given refers to cpd with unspecified sulfate ester linkage locant & (3 beta,16 beta)-isomer
more infohttp://www.curehunter.com/public/keywordSummaryC024368-16-hydroxydehydroepiandrosterone-sulfate.do

Stormy Weather w/ True Confessions - Mens Pheromone Fragrance Reviews - Perfume Chat and Trading PostStormy Weather w/ True Confessions - Men's Pheromone Fragrance Reviews - Perfume Chat and Trading Post

... the much celebrated combination of Beta and Alpha Androstenols, which purportedly encourages approach-ability, chattiness, and ...
more infohttp://lovepotion.invisionzone.com/topic/11780-stormy-weather-w-true-confessions/

Tomás Novák - NeL.eduTomás Novák - NeL.edu

Journal Article 2009; 30(3): 368-372 PubMed PMID: 19855361 Keywords: Adult, Androstenols:blood, Dehydroepiandrosterone:analogs ...
more infohttp://www.nel.edu/novak-6431/

Tomás Novák - NeL.eduTomás Novák - NeL.edu

Journal Article 2009; 30(3): 368-372 PubMed PMID: 19855361 Keywords: Adult, Androstenols:blood, Dehydroepiandrosterone:analogs ...
more infohttp://www.nel.edu/novak-9169/